ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Acumen Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.77+0.08 (+4.73%)
Close on Oct 19, 2026
- Market cap
- $127.88M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 48.8% | -96.2% | |
| Return on assets | – | – | -67.1% | |
| Current ratio | – | – | 4.07 | |
| Interest coverage | – | – | -29.3× | |
| Diluted shares | – | 0M | 61M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Acumen Pharmaceuticals generated $297.93M from operations and spent $326.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$297.93M
Used
$326.00K
Capital expenditure$326.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$121.34M
- Cash generatingOperating cash flow above zero-$115.54M
- Return on assets improvedROA up on the prior year-33.0% → -50.8%
- Earnings backed by cashOperating cash flow above net income-$115.54M vs -$121.34M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.46 → 4.07
- No dilutionShare count did not rise60M → 61M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –